|
|
Phase II Study of Paclitaxel in Patients With Locally Advanced, Metastatic, or Recurrent Squamous Cell Carcinoma of the Vulva
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
EORTC-55985 NCT00014599
|
|
|
Objectives - Determine the therapeutic activity of paclitaxel in patients with locally advanced, metastatic, or recurrent squamous cell carcinoma of the vulva.
- Determine the objective response rate and duration of response in these patients treated with this drug.
- Determine the acute side effects of this drug in these patients.
Entry Criteria Disease Characteristics:
- Histologically confirmed squamous cell carcinoma of the vulva
- Not suitable for radiotherapy or surgery as
first-line treatment
- Measurable or evaluable disease
- At least 1 bidimensionally measurable target lesion
- Measurable metastatic disease outside previously
irradiated areas
OR - Local recurrence within a previously treated area
OR - Local lesions showing progression while on treatment
- No brain metastasis
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: - No prior chemotherapy except as concurrent therapy with
radiotherapy
Endocrine therapy: Radiotherapy: - See Disease Characteristics
- See Chemotherapy
- No concurrent radiotherapy
Surgery: Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: Hepatic: - Bilirubin no greater than 1.5 mg/dL
- AST/ALT less than 2 times upper limit of normal
Renal: - Creatinine clearance greater than 60 mL/min
Cardiovascular: - No prior or concurrent cardiac disease (i.e., uncontrolled
high blood pressure, unstable angina, congestive heart failure,
myocardial infarction within the past year, cardiac ventricular arrhythmia
requiring medication, or 2nd or 3rd degree heart block)
Other: - No peripheral neuropathy greater than grade 1
- No serious active infection
- No prior allergic reaction to drugs containing Cremophor
EL
- No other serious medical, psychological, familial, or social
condition that would preclude study
- Not pregnant or nursing
- Fertile patients must use effective contraception
Expected Enrollment A total of 16-29 patients will be accrued for this study. Outline This is a multicenter study. Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats
every 21 days for a maximum of 10 courses in the absence of disease
progression or unacceptable toxicity. Patients are followed every 9 weeks.
Trial Contact Information
Trial Lead Organizations European Organization for Research and Treatment of Cancer | | | Els Witteveen, MD, PhD, Study coordinator | | | |
Registry Information | | Official Title | | Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy | | Trial Start Date | | 2001-02-07 | | Registered in ClinicalTrials.gov | | NCT00014599 | | Date Submitted to PDQ | | 2001-02-27 | | Information Last Verified | | 2005-02-23 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|